



## NGM Bio to Participate in Upcoming Investor Conferences

November 9, 2021

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming 2021 virtual investor conferences:

### **Stifel 2021 Virtual Healthcare Conference**

Monday, November 15, 2021, 2:40pm ET

### **Jefferies London Healthcare Conference**

Thursday-Friday, November 18-19, 2021; presentation available on-demand beginning November 18, 2021, 3:00am ET

### **33rd Annual Piper Sandler Healthcare Conference**

Tuesday-Thursday, November 30-December 2, 2021; presentation available on-demand beginning November 22, 2021, 10:00am ET

### **Evercore ISI Healthcare Conference**

Wednesday, December 1, 2021, 1:25pm ET

Live webcasts of presentations will be available under the Investors and Media section of NGM's website at <https://ir.ngmbio.com/events-presentations>. A replay of each presentation will be archived on NGM's site for at least 30 days following the event.

### **About NGM Biopharmaceuticals, Inc.**

NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying retinal diseases, cancer and liver and metabolic diseases. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. All of our therapeutics have been generated by our in-house discovery engine; today, we have seven disclosed programs, including four in Phase 2 or 2b studies, across three therapeutics areas. Visit us at [www.ngmbio.com](http://www.ngmbio.com) for more information.

### **Investor Contact:**

Brian Schoelkopf  
[ir@ngmbio.com](mailto:ir@ngmbio.com)

### **Media Contact:**

Liz Melone  
[media@ngmbio.com](mailto:media@ngmbio.com)